Cancer-Related Immune Therapies

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Jacc: Cardiooncology Pub Date : 2025-08-01 DOI:10.1016/j.jaccao.2025.06.008

Kapka Miteva PhD , Markus S. Anker MD , Henry Fechner DVM , Lorenz Lehmann MD , Sophie Van Linthout PhD

引用次数: 0

Abstract

Immune-based therapies—including immune checkpoint inhibitors, bispecific T cell engagers, chimeric antigen receptor T cells, and tumor-infiltrating lymphocytes— not only have transformed cancer treatment, but also have introduced significant cardiovascular complications, posing new challenges for cardio-oncology. Growing recognition of cardiovascular immune-related adverse events has spurred research into the immune–cardiovascular interface, particularly dysregulated signaling, T cell overactivation, and cytokine release. This review synthesizes recent insights into the role of immune checkpoints in cardiovascular disease, the mechanisms of immune checkpoint inhibitor– and T cell–induced cardiotoxicity, and the therapeutic potential of immune checkpoint modulation and chimeric antigen receptor T cell therapy in cardiovascular applications.

查看原文本刊更多论文

癌症相关免疫疗法

免疫疗法——包括免疫检查点抑制剂、双特异性T细胞结合剂、嵌合抗原受体T细胞和肿瘤浸润淋巴细胞——不仅改变了癌症治疗，而且还引入了显著的心血管并发症，对心脏肿瘤学提出了新的挑战。越来越多的心血管免疫相关不良事件的认识刺激了对免疫-心血管界面的研究，特别是信号失调、T细胞过度激活和细胞因子释放。本文综述了免疫检查点在心血管疾病中的作用、免疫检查点抑制剂和T细胞诱导的心脏毒性机制、免疫检查点调节和嵌合抗原受体T细胞治疗在心血管疾病中的应用潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jacc: Cardiooncology Multiple-

CiteScore

12.50

自引率

6.30%

发文量

106

期刊介绍： JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.